Genome Sequences of 17 Diverse Pseudomonas aeruginosa Phages.

Here, we describe genome sequences of 17 phages, including therapeutic candidates. They belong to the families , , and and six different genera. The genomes ranged in size from 42,788 to 88,805 bp, with G+C contents of 52.

Synergistic Killing and Re-Sensitization of to Antibiotics by Phage-Antibiotic Combination Treatment.

Multidrug-resistant (MDR) infections pose a serious health threat. Bacteriophage-antibiotic combination therapy is a promising candidate for combating these infections. A 5-phage cocktail, PAM2H, was tested in combination with antibiotics (ceftazidime, ciprofloxacin, gentamicin, meropenem) to determine if PAM2H enhances antibiotic activity.

Complete Genome Sequences of 10 Phages Lytic against Multidrug-Resistant Pseudomonas aeruginosa.

We report the genome sequences of 10 phages studied for their potential for formulation of a therapeutic cocktail; they represent the families , , and Genome sizes ranged from 43,299 to 88,728 nucleotides, with G+C contents of 52.1% to 62.2%.

Effects of Bacteriophage K on Expression of Cytokines and Activation Markers by Human Dendritic Cells In Vitro.

A potential concern with bacteriophage (phage) therapeutics is a host-versus-phage response in which the immune system may neutralize or destroy phage particles and thus impair therapeutic efficacy, or a strong inflammatory response to repeated phage exposure might endanger the patient. Current literature is discrepant with regard to the nature and magnitude of innate and adaptive immune response to phages. The purpose of this work was to study the potential effects of phage K on the activation of human monocyte-derived dendritic cells.

CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells.

Synthetic peptides encoding protective pathogen-derived epitopes represent--in principle--an ideal approach to T-cell vaccination. Empirically, however, these strategies have not been successful. In the current study, we profiled the early activation of CD8+ T cells by MHC class I-restricted peptide immunization to better understand the biology of this response.

Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.

Liver-stage antigen 1 (LSA1) is expressed by Plasmodium falciparum only during the intrahepatic cell stage of the parasite's development. Immunoepidemiological studies in regions where malaria is endemic suggested an association between the level of LSA1-specific humoral and cell-mediated immune responses and susceptibility to clinical malaria. A recombinant LSA1 protein, FMP011, has been manufactured as a preerythrocytic vaccine to induce an immune response that would have the effect of controlling parasitemia and disease in humans.